Catechol compound as well as preparation method and application thereof

By developing spherulin fermented by micromonosporus, the existing anti-fibrosis and anti-inflammatory treatments have been solved, providing effective inhibition of liver fibrosis and inflammation, demonstrating its anti-fibrosis in the anti-fibrosis Potential in chemistry and anti-inflammatory treatment.

CN118908888AActive Publication Date: 2024-11-08MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI

Patent Information

Application Number
CN202410968357.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-08
Estimated Expiration
2044-07-18

AI Technical Summary

Technical Problem

Existing anti-fibrosis and anti-inflammatory treatments have problems of low efficiency, high toxicity and narrow treatment scope, especially when targeting liver fibrosis and inflammation-related diseases, there is a lack of effective natural drug solutions.

Method used

A mucouschelin compound modified with hydroxyl groups on the fat chain obtained by fermentation of micromonosporus microsporus was developed, called sporalin, through its inhibitory effect on human liver stellate cells and mouse abdominal macrophages. Anti-fibrosis and anti-inflammatory treatment options are provided. Sporalin has a concentration-dependent inhibitory effect on the expression of fibrosis marker genes and inflammatory factors, and is less cytotoxic.

Benefits of technology

Spollol significantly inhibits the expression of fibrosis marker genes in human liver stellate cells and the expression of inflammatory factors in mouse peritoneal macrophages at low concentrations, providing potential anti-fibrosis and anti-inflammatory treatments, while at the same time its low cytotoxicity Make it suitable for clinical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908888A_ABST
    Figure CN118908888A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of microbiology and pharmacy, in particular to a catechol compound and a preparation method and application thereof. The catechol compound is characterized in that the catechol compound has the following structural formula: # imgabs0 #, wherein R1 and R2 represent alkyl, phenyl or substituted phenyl. According to the catechol compound and the preparation method and application thereof, the catechol compound is a natural product obtained through microbial fermentation, the anti-fibrosis and anti-inflammatory activity of the catechol compound is good, and the catechol compound has the clinical application prospect of anti-fibrosis and anti-inflammatory treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of microbiology and pharmacy, and in particular to a catechol compound and a preparation method and application thereof. Background Art

[0002] Catechol is the common name for catechol. Catechol iron carriers from microorganisms are usually catecholamide compounds formed by the condensation of one or more 2,3-dihydroxybenzoic acid (DHBA) with amino acids or short peptides and dehydration. Take enterobactin or entererochelin found in Escherichia coli as an example. Its structure contains 3 DHB and 6 phenolic hydroxyl groups, which can react with trivalent iron ions (Fe 3+ ) forms an ion chelate mainly composed of hexadentate octahedrons, namely an iron-siderophore complex, which helps microorganisms transport iron ions into cells and exert biological functions. Catechol-type siderophore compounds are often named after the bacteria that produce them, such as Serratia ( Serratia ) strains are called Serratiochelins. Myxochelins are mainly produced by myxobacteria ( Myxobacteria ) produced by the myxobacteria, including myxochelin AD, hyalachelins A−C, myxochelin N and O, myxochelin N1, and myxochelin B succinate. In addition to the 11 myxochelins produced by myxobacteria, the fish-killing Pseudomonas Pseudoalteromonas piscicida A new mucochelin, Pseudochelin A, was also discovered in S2040. The synthesis of natural mucochelins depends on the catalysis of nonribosomal peptide synthetase (NRPS). With the assistance of enzymes MxcE and MxcF, nonribosomal peptide synthetase (NRPS) MxcG connects two molecules of 2,3-DHBA units to the amino group of L-lysine, and the resulting thioester intermediate is catalyzed by mxc The reductase domain of G is reduced to an aldehyde intermediate, which is further reduced to form mucochelin A, or catalyzed by aminotransferase (MxcL) to form mucochelin B. 2,3-DHBA is synthesized by the biosynthetic gene mxcThe protein encoded by CDEF is used to catalyze the formation of 2,3-DHBA. Studies have shown that the key synthase MxcE of some strains is not specific to the substrate 2,3-DHBA, but has a certain tolerance, thus forming atypical myxochelins such as Myxochelin N and Myxochelin O. Although they no longer have groups that chelate iron ions and are not iron carriers, from the perspective of biosynthesis, they are consistent with the typical myxochelin synthesis pathway and are still called myxochelins. For this type of substrate-tolerant strain, the precursor-directed biosynthesis (PDB) strategy was adopted to obtain 31 non-natural myxochelin compounds by adding structural analogs of the substrate 2,3-DHBA.

[0003] Previous studies have shown that myxochelin has antibacterial, antioxidant, and anti-tumor activities. Among them, myxochelin has been studied the most as a 5-lipoxygenase (5-LOX) inhibitor. As a key upstream enzyme for the production of leukotriene (LT), 5-LOX has become an important target for drugs to treat corresponding diseases. A-64077, also known as Zileuton, developed by Abbott Pharmaceuticals in the United States, is the only 5-LOX inhibitor currently on the market, mainly for the prevention and treatment of chronic asthma in patients aged 12 and above. In addition, anti-tumor cell proliferation and anti-tumor cell metastasis and invasion are also the focus of myxochelin activity research. Studies have shown that Myxochelin A has a significant inhibitory effect on the metastasis and invasion of mouse colon cancer 26-L5 cells at a non-cytotoxic concentration. Summary of the invention

[0004] The invention provides a catechol compound and a preparation method and application thereof, which are used for anti-fibrosis and anti-inflammatory treatment.

[0005] In a first aspect, the present invention first provides a catechol compound having any of the following structural formulas: ; Wherein, R1 and R2 represent alkyl, phenyl or substituted phenyl.

[0006] The present invention first discovered mycochelins with modified hydroxyl groups on the fatty chain. Since they were first discovered from the secondary metabolites of Micromonospora, they were named Sporachelin. The activity study of Sporachelin showed for the first time that Sporachelin has an effect on the expression of LX-2 fibrosis marker gene in human hepatic stellate cells. COL1A1 , ACTA2 and TGFB1 The expression of β-catenin was inhibited in a concentration-dependent manner and the cytotoxicity against human hepatic stellate cells LX-2 was low (CC 50>200 μM), thus suggesting that it can be used for anti-fibrosis treatment. In addition, at low concentrations, spore sequestrants had an effect on human 5-lipoxygenase activity and the expression of the inflammatory marker gene Raw264.7 in mouse peritoneal macrophages. Tnfα and Cox2 It also has a strong inhibitory effect on expression, suggesting that it can be used for anti-inflammatory treatment.

[0007] Preferably, R1 and R2 represent C1-C7 alkyl, phenyl or substituted phenyl; more preferably, R1 and R2 represent C1-C3 alkyl, phenyl or substituted phenyl; further preferably, R1 represents methyl, ethyl, isopropyl, benzyl or p-hydroxybenzyl; R2 represents benzyl.

[0008] As a preferred embodiment of the present invention, the catechol compound comprises: .

[0009] The molecular formula of spore chelator A is C 28 H 30 N2O8, molecular weight is 522; the molecular formula of spore sequestrant A1 is C 27 H 29 N3O6, molecular weight is 491; the molecular formula of spore sequestrant B is C 28 H 30 N2O9, molecular weight is 538; the molecular formula of spore chelating agent C is C 22 H 26 N2O8, molecular weight is 446; the molecular formula of spore chelating agent D is C 23 H 28 N2O8, molecular weight is 460; the molecular formula of spore sequestrant E is C 24 H 30 N2O8, molecular weight is 474.

[0010] In a second aspect, the present invention provides the use of the catechol compounds in the preparation of anti-fibrosis drugs.

[0011] In the present invention, pharmaceutically acceptable salts of catechol compounds also belong to the protection scope of the present invention. The catechol compounds of the present invention can be used in the form of pharmaceutically acceptable salts derived from inorganic acids or organic acids. The term "pharmaceutically acceptable salt" refers to salts that are suitable for contact with human and lower animal tissues without excessive toxicity, irritation, allergic reactions, etc., within the scope of reliable medical judgment, and are commensurate with a reasonable effect / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, SM Berge, et al., J. Pharmaceutical Sciences, 1977, 66: 1 describe pharmaceutically acceptable salts in detail. The salts can be prepared by reacting the free base functionality of the compound of the present invention with a suitable organic acid.

[0012] In a third aspect, the present invention also provides the use of the pharmaceutically acceptable salt of the catechol compound in the preparation of anti-fibrosis drugs.

[0013] In a fourth aspect, the present invention also provides use of the catechol compounds or pharmaceutically acceptable salts thereof in the preparation of anti-inflammatory drugs.

[0014] In a fifth aspect, the present invention also provides an anti-fibrosis drug, which contains the catechol compound or a pharmaceutically acceptable salt thereof.

[0015] In a sixth aspect, the present invention further provides an anti-inflammatory drug, which contains the catechol compound or a pharmaceutically acceptable salt thereof.

[0016] In the present invention, the anti-fibrosis drug or anti-inflammatory drug may be a drug for treating and / or preventing the disease.

[0017] In the present invention, the anti-fibrosis drug or anti-inflammatory drug may contain, in addition to the catechol compound or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier may be 0.1 to 99.9% by weight of the total weight of the anti-fibrosis drug or anti-inflammatory drug.

[0018] In the present invention, the pharmaceutically acceptable carrier includes one or more of microcrystalline cellulose, sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, mannitol, sorbitol, sorbic acid or potassium salt, surfactant, polyethylene glycol, cyclodextrin, β-cyclodextrin, phospholipid materials, kaolin, talc, calcium stearate, magnesium stearate and microcrystals.

[0019] The anti-fibrosis drug or anti-inflammatory drug of the present invention can be prepared into any desired dosage form such as tablets, capsules, injections, ointments, creams, and sprays.

[0020] In the present invention, the active ingredients of the anti-fibrosis drug or anti-inflammatory drug include the catechol compound or a pharmaceutically acceptable salt thereof. The active ingredients of the anti-liver fibrosis drug or anti-inflammatory drug may also contain other biological components or non-biological components. The other active ingredients can be determined by those skilled in the art according to the anti-fibrosis or anti-inflammatory effects.

[0021] In a seventh aspect, the present invention also provides the use of the catechol compounds in treating fibrotic diseases or inflammation.

[0022] In the present invention, the fibrotic disease may be caused by inflammation, and may include liver fibrosis, lung fibrosis, kidney fibrosis or cardiac fibrosis.

[0023] The compounds spore sequestrant AE and spore sequestrant A1 of the present invention inhibit the fibrosis marker gene LX-2 of human hepatic stellate cells at 1 μM and 5 μM concentrations. COL1A1 , ACTA2 and TGFB1 The expression of β-catenin was inhibited in a concentration-dependent manner and the cytotoxicity to human hepatic stellate cells LX-2 was low (CC 50 >200μM), which can be used for the treatment of liver fibrosis. In addition, the inhibition rate of spore sequestrant AE and spore sequestrant A1 on human 5-lipoxygenase at a concentration of 2μM was >50%, and at the same time, the inflammatory marker gene Raw264.7 in mouse peritoneal macrophages was inhibited at a concentration of 1μM. Tnfα and Cox2 It also has a good inhibitory effect on expression and can therefore be used for anti-inflammatory treatment.

[0024] In the present invention, sporechelin AE and sporechelin A1 are natural products obtained by microbial fermentation, and the raw materials are easily available, so they can be used as anti-fibrosis or anti-inflammatory lead compounds for structural optimization to develop anti-fibrosis or anti-inflammatory drugs with better activity. Sporchelin AE and sporechelin A1 are used as active ingredients and are compatible with one or more pharmaceutically acceptable carriers, excipients or adjuvants to prepare anti-fibrosis or anti-inflammatory pharmaceutical compositions. Sporchelin AE and sporechelin A1 and their pharmaceutical compositions can be used for the clinical treatment of fibrosis or inflammation.

[0025] In an eighth aspect, the present invention also provides a method for preparing the catechol compounds, comprising S1 to S2, wherein S1: fermenting and culturing Micromonospora to obtain a fermentation broth; S2: extracting and separating the catechol compounds from the fermentation broth.

[0026] Preferably, the Micromonospora is Micromonospora sp. TMD166, whose registration number in the General Microbiological Center of China Culture Collection Administration is CGMCC No. 21622.

[0027] In the present invention, in the preparation method of the catechol compounds, the culture medium can be a culture medium capable of culturing actinomycetes, which can be a solid culture medium, a semi-solid culture medium or a liquid culture medium. The actinomycete culture medium can be an International Streptomyces Program culture medium (ISP2, ISP3, ISP4, etc.), Gao's medium No. 1, trypticase soy broth culture medium (TSB) or other actinomycete fermentation culture medium well known to professionals in the field. The ISP2 culture medium can be made of glucose, malt extract, yeast extract and water, or can be made of glucose, malt extract, yeast extract, inorganic salts and water, or can be made of glucose, malt extract, yeast extract, inorganic salts, vitamin complexes and water. The Gao's medium No. 1 can be made of starch, inorganic salts and water, or can be made of starch, inorganic salts, vitamin complexes and water. The trypticase soy broth medium can be made of trypticase peptone, soytone, glucose and water, or can be made of trypticase peptone, soytone, glucose, inorganic salts and water, or can be made of trypticase peptone, soytone, glucose, inorganic salts, vitamin complex and water. The other actinomycete fermentation medium well known to professionals in the field can be made of one or more fast-acting, slow-acting carbon sources, one or more fast-acting, slow-acting nitrogen sources, water and / or inorganic salts. Carbon source is a type of nutrient for microbial growth, which is a carbon-containing compound, including fast-acting and slow-acting carbon sources such as sugars, oils, organic acids and organic acid esters and small molecule alcohols. Nitrogen source refers to a substance that provides nitrogen elements required for microbial nutrition, including fast-acting and slow-acting nitrogen sources such as peanut cake powder, soybean cake powder, yeast powder, peptone, ammonia water, ammonium salts and nitrates.

[0028] The preparation method of the catechol compounds can be liquid fermentation preparation.

[0029] In the above-mentioned liquid fermentation for preparing the catechol compounds, the culture medium may be a liquid culture medium, and the fermentation product may be a liquid fermentation product.

[0030] Preferably, the fermentation culture comprises: inoculating the Micromonospora on a seed culture medium for culture, and then transferring to a fermentation culture medium for shaking culture.

[0031] Preferably, the culture conditions on the seed culture medium are 28-30°C, 150-200 r / min, and the culture time is 3-4 d; the culture conditions on the fermentation culture medium are 28-30°C, 150-200 r / min, and the culture time is 6-7 d.

[0032] Preferably, the seed culture medium and the fermentation culture medium have the same formula; further preferably, medium No. 38 is selected; further preferably, the specific ingredients are: 4.0g glucose, 4.0g yeast powder, 5.0g malt extract powder, 0.001g ZnSO4.7H2O, 0.001g MnCl2.4H2O, 0.002g FeSO4.7H2O, 0.001g phenylalanine, 0.0003g alanine, 0.001g vitamin B1, 0.001g vitamin B2, 0.001g vitamin B6, 0.001g niacin, 0.001g biotin, and 1.0L sterile distilled water; the pH of the seed culture medium and the fermentation culture medium is 7.2.

[0033] Preferably, the S2 includes S21~S22, S21: centrifuging the fermentation broth to obtain a supernatant and mycelium, extracting the supernatant to obtain a supernatant extract; S22: preliminarily separating the supernatant extract by gel column chromatography, then separating it by reverse phase silica gel column chromatography, gradient eluting with a solvent, and finally preparing and separating by HPLC to obtain catechol compounds.

[0034] Preferably, during the extraction treatment, the extraction solvent includes one or more of chloroform, dichloromethane and ethyl acetate; in one embodiment of the present invention, it is ethyl acetate.

[0035] Preferably, the medium used in the gel column chromatography separation includes Sephadex LH-20 or Tosoh Toyopearl HW-40; in one embodiment of the present invention, it is Sephadex LH-20.

[0036] Preferably, the medium used in the reverse phase silica gel column includes C18 reverse phase silica gel or phenyl reverse phase silica gel; in one embodiment of the present invention, it is C18 reverse phase silica gel.

[0037] Preferably, the chromatographic column used in the HPLC preparative separation comprises a C18 chromatographic column, a C8 chromatographic column, a C3 chromatographic column or a phenyl bonded column. In one embodiment of the present invention, it is a C18 chromatographic column or a C8 chromatographic column.

[0038] Preferably, the mobile phase used in the gel column chromatography includes one or more of chloroform, dichloromethane, ethyl acetate, methanol and other alcohols with a carbon chain of ≤4, acetone and butanone; or a mixed solution of one or more of the above solvents and water; in one embodiment of the present invention, it is methanol.

[0039] Preferably, the solution used for the reverse phase silica gel column chromatography separation includes one or more of acetone aqueous solution, alcohol solution with a carbon chain of ≤4, acetonitrile aqueous solution and methanol; in one embodiment of the present invention, it is methanol aqueous solution.

[0040] Preferably, the mobile phase used in the HPLC preparative separation comprises one or more of an acetone aqueous solution, an alcohol solution with a carbon chain ≤ 4, and an acetonitrile aqueous solution; in one embodiment of the present invention, it is an acetonitrile aqueous solution.

[0041] As a preferred embodiment of the present invention, the medium used in the gel column chromatography can be Sephadex LH-20, the mobile phase used can be methanol, and the liquid eluted with the mobile phase is named as component L1-L 10 In the above liquid fermentation preparation, the preparation method includes separating sporechelin AE and sporechelin A1 from the component L3.

[0042] In the above-mentioned liquid fermentation to prepare spore sequestering agent AE and spore sequestering agent A1, separating spore sequestering agent AE and spore sequestering agent A1 from the component L3 comprises subjecting the component L3 to reverse silica gel column chromatography, gradient eluting with 10%-100% methanol aqueous solution, and naming the liquid eluted with the mobile phase as L 3-1 -L 3-11 , component L 3-6 Sporochelin C and component L were also obtained by HPLC preparation and separation. 3-7 Sporochelin BD and component L were also obtained by HPLC preparation and separation. 3-8 Sporochelin BE and A1 were also obtained by HPLC preparation and separation, and component L 3-9 Sporochelin A is obtained by HPLC preparation and separation. The mobile phase used in the HPLC preparation and separation can be an acetonitrile and water system.

[0043] The present invention provides a catechol compound and a preparation method and application thereof. The catechol compound is a natural product obtained by microbial fermentation, has good anti-fibrosis and anti-inflammatory activities, and has good clinical application prospects for anti-fibrosis and anti-inflammatory treatments. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] In order to more clearly illustrate the technical solutions in the present invention or the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0045] Figure 1 The compound represented by formula I-VI 1 H- 1 H COSY, HMBC related signals.

[0046] Figure 2 This is a high-resolution electrospray ionization mass spectrum of the compound represented by formula I.

[0047] Figure 3 The compound shown in formula I 1 H NMR spectrum.

[0048] Figure 4 The compound shown in formula I 13 C NMR spectrum.

[0049] Figure 5 This is a high-resolution electrospray ionization mass spectrum of the compound represented by formula II.

[0050] Figure 6 The compound represented by formula II 1 H NMR spectrum.

[0051] Figure 7 The compound represented by formula II 13 C NMR spectrum.

[0052] Figure 8 This is a high-resolution electrospray ionization mass spectrum of the compound represented by formula III.

[0053] Fig. 9 The compound represented by formula III 1 H NMR spectrum.

[0054] Fig.10 The compound represented by formula III 13 C NMR spectrum.

[0055] Fig.11 This is a high-resolution electrospray mass spectrum of the compound represented by formula IV.

[0056] Fig.12 The compound represented by formula IV 1 H NMR spectrum.

[0057] Fig.13 The compound represented by formula IV 13 C NMR spectrum.

[0058] Fig.14 This is a high-resolution electrospray ionization mass spectrum of the compound represented by formula V.

[0059] Fig.15 The compound represented by formula V 1 H NMR spectrum.

[0060] Fig.16 The compound represented by formula V 13 C NMR spectrum.

[0061] Fig.17 This is a high-resolution electrospray ionization mass spectrum of the compound represented by formula VI.

[0062] Fig.18The compound represented by formula VI 1 H NMR spectrum.

[0063] Fig.19 The compound represented by formula VI 13 C NMR spectrum.

[0064] Fig. 20 The compound represented by formula I and quantum chemical calculation 2S / 2R -Electron circular dichroism spectrum of sporechelin A.

[0065] Fig.21 It is the electronic circular dichroism spectrum of the compound represented by formula I-VI.

[0066] Fig. 22 The cytotoxicity of sporechelin AE and sporechelin A1 in LX-2 cells.

[0067] Fig.23 The cytotoxicity of spore sequestrants A-E and spore sequestrant A1 in NIH3T3 cells stimulated with TGF-β1.

[0068] Fig.24 Toxicity evaluation of sporechelin AE and sporechelin A1 in LPS-induced Raw264.7 cells (1 μM). DETAILED DESCRIPTION

[0069] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be clearly and completely described below in conjunction with the drawings of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0070] Example 1

[0071] This embodiment provides a catechol compound and a preparation method thereof, comprising: 1. Micromonospora Micromonospora Fermentation of sp. TMD166

[0072] The spore liquid of the strain was inoculated on a No. 38 medium plate. The medium formula was: 4.0g glucose, 4.0g yeast extract, 5.0g malt extract, 0.001g ZnSO4.7H2O, 0.001g MnCl2.4H2O, 0.002g FeSO4.7H2O, 0.001g phenylalanine, 0.0003g alanine, 0.001g vitamin B1, 0.001g vitamin B2, 0.001g vitamin B6, 0.001g nicotinic acid, 0.001g biotin, 15g agar, 1.0L sterile distilled water, pH 7.2. The plate was placed at 28°C for 7-10 days. A sterile bamboo stick was used to take a 1 cm 2 The agar block containing bacteria was inoculated into 100 mL of liquid No. 38 culture medium in a 500 mL Erlenmeyer flask and cultured in a shake flask at 28°C and 180 rpm for 3-4 days to prepare the seed solution.

[0073] Take 100mL of the above seed solution and transfer it to a 5L conical flask containing 1L of No. 38 liquid culture medium, a total of 30L, 28℃, 180 rpm, shake the flask for 6-7 days to obtain Micromonospora Micromonospora sp. TMD166 fermentation products.

[0074] 2. Micromonospora Micromonospora Extraction of fermentation products of sp. TMD166 and preparation of crude extracts

[0075] The liquid fermentation product (30 L) obtained above was centrifuged to obtain a supernatant, which was extracted 3 times (30 L × 3) with an equal volume of ethyl acetate, and concentrated under reduced pressure at low temperature to remove the organic solvent to obtain a crude ethyl acetate extract (3.2 g).

[0076] 3. Isolation, preparation and structural identification of compounds represented by formula I-VI

[0077] The crude ethyl acetate extract obtained above was dissolved in methanol and separated by gel column chromatography, with pure methanol solution as the mobile phase. The separation medium used in the gel column chromatography was Sephadex LH-20, the column size was 25 × 2400 mm (diameter × length), the column volume was 1100 mL, and the eluted liquid was collected continuously from the beginning of the elution procedure, 15 mL was collected in each tube, and a total of 99 tubes were collected. The collected effluent was detected by TLC and combined to obtain 10 components (L1-L 10 ). Fraction L3 (732 mg, i.e., the collected solution from tubes 17 to 26) was purified by C 18 Reversed phase flash column chromatography, C 18The medium used in the reversed-phase silica gel column was column chromatography reversed-phase silica gel (50 g). The specifications of the reversed-phase silica gel column used were 45 × 90 mm (diameter × length). The elution program was 0-100 min, 10%-100% methanol, 100-120 min, 100% methanol, 15 mL / min. The eluted liquid was collected continuously from the beginning of the elution program, 20 mL was collected in each tube, and a total of 90 tubes were collected. They were combined according to the UV absorption graph to obtain 11 components ( L 3-1 -L 3-11 ); component L 3-6 (32 mg, collected from tubes 33 to 38) was separated and purified by HPLC (chromatographic column parameters: Capcell-Pak-C8DD, 5μm, 10 mm × 250 mm), and eluted with acetonitrile-water solution (acetonitrile and water volume ratio of 38:62) (flow rate of 2mL / min) to obtain the compound of formula IV (4.6 mg, t R =25.7 min); component L 3-7 (39 mg, collected from tubes 39 to 42) was separated and purified by HPLC (chromatographic column parameters: Capcell-Pak- C 18 MGⅡ, 5μm, 10 mm × 250mm), eluted with acetonitrile-water solution (acetonitrile and water volume ratio of 43:57) (flow rate of 2mL / min) to obtain the compound of formula III (9 mg, t R =23.0 min), the compound described in formula Ⅳ (4 mg, t R =18.2 min), the compound of formula V (6.3 mg, t R =25.7 min); component L 3-8 (22 mg, collected from tubes 43 to 46) were separated and purified by HPLC (chromatographic column parameters: Capcell-Pak- C 18 MGⅡ, 5μm, 10 mm × 250 mm), eluted with acetonitrile-water solution (acetonitrile and water volume ratio of 43:57) (flow rate of 2mL / min) to obtain the compound of formula Ⅱ (0.9 mg, t R = 22.1 min), the compound of formula III (1.3 mg, t R = 22.6 min), the compound of formula Ⅳ (1.6 mg, t R =18.3 min), the compound described in formula V (0.8 mg, tR = 25.4 min), the compound of formula VI (5.6 mg, t R =36.0 min), component L 3-9 (62 mg, collected from tubes 47 to 57) were separated and purified by HPLC (chromatographic column parameters: Capcell-Pak- C 18 MGⅡ, 5μm, 10 mm × 250mm), eluted with acetonitrile-water solution (acetonitrile and water volume ratio of 45:55) (flow rate of 2mL / min) to obtain the compound of formula I (42 mg, t R =44.3 min).

[0078] Structural identification of the compound spore sequestrant A shown in formula I: High resolution electron spray mass spectrometry (HRESIMS) shows quasi-molecular ion peaks m / z 523.2081 [M+H] + , combined with nuclear magnetic resonance spectroscopy (NMR) data, its molecular formula was determined to be C 28 H 31 N2O8 (theoretical value is 523.2080, Figure 2 ), the degree of unsaturation is 15. The compound represented by formula I 1 H NMR spectra (CD3OD, Figure 3 , Table 1) shows 11 aromatic hydrogen proton signals in the low field region of 6.68-7.19 ppm, 5 methylene signals and one oxymethylene signal in the high field region of 1.46-3.61 ppm 4.21 (dd, H-1a), 4.15 (dd, H-1b), one methine signal 4.38 (m, H-2). 13 C NMR spectra (CD3OD, Figure 4 , Table 2) showed 28 carbon signals, and the DEPT and HSQC spectra showed that these carbons were 10 quaternary carbons (including 3 carbonyl carbons, 7 sp 2 quaternary carbon), 12 methine carbons [11 of which are sp 2 Hybridized carbon, one of which is nitrogen-attached carbon 49.6 (C-5')], 6 methylene carbons [one of which is connected to oxygen 67.2(C-1)]. The above NMR data are similar to those of Myxochelin A isolated from myxobacteria (see Kunze B, Bedorf N, Kohl W, Höfle G, Reichenbach H. Myxochelin A, a newiron-chelating compound from Angiococcus disciformis (Myxobacterales). Production, isolation, physico-chemical and biological properties. J Antibiot[J]. 1989, 42(1):14-17.), indicating that the compound is a myxochelin derivative. The COSY spectrum correlation peak signal of the compound of formula I indicates that the structure contains the following Figure 1 The four structural fragments shown include a 2,6-diaminohexanol, a monosubstituted benzene ring, and two trisubstituted benzene rings of o-diphenol. In the HMBC spectrum, the correlation between H-6" and C-7", and the correlation between H-6' and C-7', indicate that there are two o-diphenol benzoyl fragments in the structure, the correlation between H-6 and C-7", and the correlation between H-2 and C-7', indicating that the two o-diphenol benzoyl fragments are connected to 2,6-diaminohexanol through amide bonds, confirming that the compound has a structural skeleton of mucochelin. In addition, the correlation between H-2"' and C-1"', C-3"', C-4"' and C-8"', combined with the chemical shifts of these carbons, indicates that there is a phenylacetyl unit in the structure; the correlation between C-1 and C-1"' indicates that the phenylacetyl group is connected to the C-1 position through an ester bond, thereby confirming the planar structure of the compound of formula I.

[0079] Structural identification of the compound spore sequestrant A1 represented by formula II: HRESIMS shows a quasi-molecular ion peak m / z 492.2147[M+H] + (C 27 H 30 The theoretical value of N3O6 is 492.2135, Figure 5 ), combined with NMR data, its molecular formula was determined to be C 27 H 29 N3O6, which is 31 Da less than the molecular weight of the compound of formula I. The NMR data of the compound of formula II are very similar to those of the compound of formula I ( Figure 6 , Figure 7 ), the main difference is that the compound of formula II 1 A group of 8.08, 8.65 and 8.84 hydrogen signals ( Figure 6), indicating the presence of an aromatic heterocycle in the structure. HMBC and COSY analysis showed that the heterocycle was a nicotinyl group. The correlation between H-2 and C-7' showed that the nicotinyl group was attached to the C-2 position. Therefore, the structure of the compound was determined to be as shown in Formula II.

[0080] Table 1 1H NMR data of compounds represented by formula I-VI (CD3OD, 600 MHz)

[0081] Table 2 13C NMR data of compounds represented by formula I-VI (CD3OD, 150MHz)

[0082] Structural identification of the compound spore sequestrant B represented by formula III: HRESIMS shows a quasi-molecular ion peak m / z 539.2021[M+H] + (C 28 H 31 The theoretical value of N2O9 is 539.2030, Figure 8 ), combined with NMR data, its molecular formula was determined to be C 28 H 30 N2O9, has one more oxygen atom than the compound represented by formula Ⅰ. The NMR data of the compound represented by formula Ⅲ are very similar to those of the compound represented by formula Ⅰ ( Fig. 9 , Fig.10 ), the main difference is the phenylacetyl structural fragment. The compound represented by formula III 13 C NMR has an additional oxygen-linked aromatic carbon 157.5, in addition, C-3"', C-5"', and C-7"' shifted to high field by -9.2, -13.2, and -13.2 ppm, respectively ( Fig.10 ), indicating that H-6"' of the compound represented by formula I is substituted by OH. 2D NMR data analysis further confirmed that the compound represented by formula III is the C-6"'-hydroxylation product of the compound represented by formula I.

[0083] Structural identification of the compound spore sequestrant C represented by formula Ⅳ: HRESIMS shows a quasi-molecular ion peak m / z 447.1786[M+H] + (C 22 H 27 The theoretical value of N2O8 is 447.1767, Fig.11 ), combined with NMR data, its molecular formula was determined to be C 22 H 26 N2O8, compared with the NMR data of the compound of formula Ⅰ, the compound of formula Ⅳ lacks a group of phenethyl signals ( Fig.12 , Fig.13 ),1 H NMR has an additional singlet methyl signal 2.02, and the methyl group and C-1"' have related signals in the HMBC spectrum. This suggests that the phenylacetyl group in the structure of formula I is replaced by an acetyl group. The above speculation is confirmed by 2D NMR data analysis, and the structure of the compound of formula IV is determined.

[0084] The structural identification of the compound spore sequestrant D shown in formula V is as follows: white powder, easily soluble in methanol, chloroform and DMSO. High resolution electron spray mass spectrometry (HRESIMS) shows a quasi-molecular ion peak m / z 461.1914 [M+H] + (C 23 H 29 The theoretical value of N2O8 is 461.1924, Fig.14 ), combined with NMR data, its molecular formula was determined to be C 23 H 28 N2O8. The NMR data of the compound of formula V is very similar to that of the compound of formula IV, except that 1 H and 13 There is an additional methylene signal in C NMR ( 2.32, 28.2) ( Fig.15 , Fig.16 ), and the methyl carbon signal in the compound of formula IV shifts 11.3 ppm to the upfield, and C-1"' shifts 3.3 ppm to the downfield, and 1 H- 1 H-2"'(q, 2.32) and H-3"'(t, 1.07) and the correlation between H-2"' and C-1"' ( 176.1) showed that the acetyl group in the structure of formula IV was replaced by propionyl group, and the structure of the compound shown in formula V was determined and named as sporechelin D.

[0085] Structural identification of the compound spore sequestrant E represented by formula VI: High-resolution electron spray mass spectrometry (HR-ESI-MS) shows quasi-molecular ion peaks m / z 475.2063 [M+H] + (C 24 H 31 The theoretical value of N2O8 is 475.2080, Fig.17 ), combined with NMR data, its molecular formula was determined to be C 24 H 30 N2O8, has one more methylene group than the compound of formula V. Compared with the NMR data of the compound of formula V, the 1 H and 13C NMR has one less ethyl signal and one more methine signal ( 2.53, 35.2) and two doublets of methyl signals ( 1.09, 1.10 19.2, 19.3), and C-1"' shifted 2.5 ppm downfield ( Fig.18 , Fig.19 ). Through 2D NMR data analysis, it was found that the two newly appeared methyl groups were respectively connected with the methine ( 2.53, 35.2) have relevant signals in COSY and are correlated with C-1"' in HMBC spectrum, indicating that the propionyl group in the structure of the compound of formula V is replaced by isobutyryl to obtain the compound structure of formula VI.

[0086] The absolute configuration of the compound of formula I was determined by electronic circular dichroism (ECD) calculation and literature comparison. S -1a and R The electronic circular dichroism spectra of the compound with -1b configuration were fitted. The compound of formula Ⅰ showed negative cotton effect at 220nm and 260nm, and positive cotton effect at 240nm and 310nm, which was consistent with the results of quantum chemical calculation. S - configuration compound (1a) has the same electronic circular diffraction spectrum ( Fig. 20 ), the absolute configuration of the compound described in formula I is determined to be 2 S In addition, the specific rotation value of the compound of formula I is [α] 20 D -8.8 (c 0.5, MeOH), reported in literature S -configuration myxochelin A also has a negative specific rotation value (see Furumai T, Igarashi Y. Absolute configuration and antitumor activity of myxochelin A produced by Nonomuraeapusilla TP-A0861. J. Antibiot. 2006, 59, 698-703.), further confirming that the chiral center C-2 of the compound of formula I is S The specific rotation values ​​of the compounds represented by formula II-VI are all negative, and the ECD spectrum is similar to that of the compound represented by formula I ( Fig.21 ), therefore, the absolute configuration of the compound represented by formula II-VI is also 2 S .

[0087] The physicochemical properties of the above compounds: Formula I compound: white powder, easily soluble in methanol, chloroform, and DMSO. [α] 20 D -8.8 ( c 0.5, MeOH); UV(MeOH) 207 (4.97), 249 (4.36), 312 (3.91) nm; ECD ( c 2.39×10 -4 M) 203 (0.43), 218 (-3.20), 240 (+1.46), 261 (-1.10), 314 (+0.42) nm; 1 H-NMR (CD3OD, 600 MHz) data are shown in Table 1, 13 C NMR (CD3OD, 150 MHz) data are shown in Table 2; HRESMS: m / z 523.2081 [M+H] + (C 28 H 31 The theoretical value of N2O8 is 523.2080).

[0088] Formula II compound: white powder, easily soluble in methanol, chloroform, and DMSO. [α] 20 D -4.8 ( c 0.25, MeOH);UV (MeOH) 207 (4.27), 248 (3.69), 313 (3.15) nm; ECD ( c 1.22×10 -4 M) 207 (-2.05), 216 (-3.55), 240 (-1.45), 317 (+0.32); 1 H-NMR (CD3OD, 600 MHz) data are shown in Table 1. 13 C NMR (CD3OD, 150 MHz) data are shown in Table 2; HRESMS: m / z 492.2147 [M+H] + (C 27 H 30 The theoretical value of N3O6 is 492.2135).

[0089] Formula III compound: white powder, easily soluble in methanol, chloroform, and DMSO. [α] 20 D -8.0 ( c 0.5, MeOH); UV(MeOH) 206 (4.96), 249 (4.39), 314 (3.94) nm; ECD ( c 2.32×10 -4 M) 204 (+1.52), 220 (-2.10), 240 (+1.57), 260 (-1.18), 310 (+0.31)nm; 1 H-NMR (CD3OD, 600 MHz) data are shown in Table 1, 13 C NMR (CD3OD, 150 MHz) data are shown in Table 2; HRESMS: m / z 539.2021 [M+H] + (C 28 H 31 The theoretical value of N2O9 is 539.2030).

[0090] Formula IV compound: white powder, easily soluble in methanol, chloroform, and DMSO. [α] 20 D -8.8 ( c 1.0, MeOH); UV(MeOH) 207 (4.91), 250 (4.37), 314 (3.93) nm; ECD ( c 2.80×10 -4 M) 207 (0.09), 218 (-0.87), 239 (+1.26 ), 260 (-1.37), 314 (+0.53); 1 H-NMR (CD3OD, 600 MHz) data are shown in Table 1, 13 C NMR (CD3OD, 150 MHz) data are shown in Table 2; HRESMS: m / z 447.1786 [M+H] + (C 22 H 27 The theoretical value of N2O8 is 447.1767).

[0091] Formula V compound: white powder, easily soluble in methanol, chloroform, and DMSO. [α] 20 D -4.0 ( c 0.1, MeOH); UV(MeOH) 207 (4.82), 249 (4.28), 314 (3.84) nm; ECD ( c 2.72×10 -4 M) 207 (+0.02), 215 (-0.71), 240 (+0.81), 263 (-0.76), 315 (+0.41); 1 H-NMR (CD3OD, 600 MHz) data are shown in Table 1, 13 C NMR (CD3OD, 150 MHz) data are shown in Table 2; HRESMS: m / z 461.1914 [M+H]+(C 23 H 29 The theoretical value of N2O8 is 461.1924).

[0092] Formula VI compound: white powder, easily soluble in methanol, chloroform, and DMSO. [α] 20 D -6.4 ( c 0.5, MeOH); UV(MeOH) 207 (4.91), 249 (4.37), 314 (3.92) nm; ECD ( c 2.64×10 -4 M) 207 (-0.96), 214 (-1.48), 240 (+0.90), 264 (-1.01), 314 (+0.38)nm; 1 H-NMR (CD3OD, 600 MHz) data are shown in Table 1, 13 C NMR (CD3OD, 150 MHz) data are shown in Table 2; HRESMS: m / z 475.2063 [M+H] + (C 24 H 31 The theoretical value of N2O8 is 475.2080).

[0093] 4. In vitro anti-fibrotic activity and cytotoxicity evaluation test of spore sequestrant AE and spore sequestrant A1: This part uses human hepatic stellate cells LX-2 and mouse embryonic fibroblasts NIH3T3 to evaluate the anti-fibrotic effect of the compounds. The former is a commonly used model for anti-fibrotic drug screening, and the latter is widely used in cell model studies of organ fibrosis induced by tissue hypoxia such as pulmonary fibrosis, cardiovascular fibrosis, liver fibrosis, renal fibrosis, skin fibrosis and clinical interventional embolism.

[0094] Cell culture and compound treatment: Human hepatic stellate cells LX-2 were cultured in DMEM medium (Gibco) containing 10% fetal bovine serum and 1% penicillin-streptomycin (Gibco) at a rate of 3 × 10 4 / cm 2 The cells were plated in 96-well plates at a density of 1.5 μg / mL and cultured in a 37°C 5% CO2 cell culture incubator until 60-80% of the cells were cultured. Then, the serum-free DMEM medium was replaced for starvation culture for 24 hours. Subsequently, the original culture medium was discarded, and TGF-β1 was induced at a final concentration of 2 ng / mL, and spore sequestrant AE and spore sequestrant A1 at a final concentration of 5 μM and 1 μM, or 20 μM of the positive drug EGCG (epigallocatechin-3-glycatechin) was added for 24 hours. A control group (no TGF-β1 and compounds) and a TGF-β1 induction group (only TGF-β1) were set up at the same time. The mouse embryonic fibroblast NIH3T3 was plated in the same manner as LX-2 cells. After culturing to 60-80%, 5 ng / mL of TGF-β1 and the above compounds were added for 24 hours.

[0095] Total RNA extraction and detection of fibrosis marker gene expression: The supernatant of the cell culture medium in the 96-well plate was discarded, and the total RNA of the cells was extracted using a total RNA extraction kit (Magen) according to the operating instructions. A 10 μL reaction system was prepared according to the instructions of the HiScript II One Step qRT-PCRSYBR Green Kit (Vazyme), and the one-step qRT-PCR method was used to quantitatively detect human fibrosis marker genes using an ABI 7500 Fast instrument. COL1A 1, ACTA 2. TGFB 1 and mouse fibrosis marker genes Col1a 1. Acta 2 mRNA expression, the internal reference gene is GAPDH ( Gapdh ). The primer sequences used are shown in Table 3.

[0096] Table 3 qRT-PCR primer sequences

[0097] Compared with the model group, the results of the inhibition rate of spore sequestrant AE and spore sequestrant A1 on the mRNA expression of fibrosis marker genes are shown in Tables 4 and 5: Table 4 Inhibition rate of fibrosis gene mRNA expression by sporechelin AE and sporechelin A1 in LX-2 cells (%)

[0098] Table 5 Inhibition rate of fibrosis gene mRNA expression by sporechelin AE and sporechelin A1 in NIH3T3 cells (%)

[0099] Cytotoxicity evaluation of spore sequestrant AE and spore sequestrant A1: Human hepatic stellate cells LX-2 were cultured in DMEM medium containing 10% fetal bovine serum and 1% penicillin-streptomycin at a rate of 3 × 10 4 / cm 2 The cells were plated in a 96-well plate at a density of 60-80% in a 37 °C 5% CO2 cell culture incubator, and then different concentrations of spore sequestering agent AE and spore sequestering agent A1 were added for 24 hours. The experimental group (compounds added to cells), the control group (DMSO solvent control added to cells) and the blank group (containing only culture medium) were set up. Subsequently, the culture medium was discarded, and a mixture of 90 μL of fresh culture medium and 10 μL of CCK-8 was added to each well. The cells were cultured in a 37 °C 5% CO2 cell culture incubator for 1-3 hours. The absorbance at 450 nm (OD value) was read with an enzyme reader. The cell survival rate = [(experimental group-blank group) / (control group-blank group)] × 100%, and the cell survival rate was calculated as follows: Fig. 22 Similarly, after NIH3T3 cells were stimulated with 5 ng / mL TGF-β1 and treated with 5 μM compounds for 24 hours, their cytotoxicity was evaluated. The results are shown in Fig.23 shown.

[0100] 5. Evaluation test of spore sequestrant AE and spore sequestrant A1 inhibiting 5-lipoxygenase activity in cell-free system. In this part, the inhibitory effect of compounds on 5-lipoxygenase activity was detected under in vitro cell-free conditions, and the 5-lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA) was used as a positive drug. The method is as follows: 1 μL of compound, solvent DMSO or positive drug NDGA was pre-added to a 96-well plate, mixed with 50 μL enzyme detection solution (containing 5-LOX purified active protein and detection solution), and incubated at 37°C for 15 minutes. Subsequently, 50 μL of reaction buffer (containing 6 μM arachidonic acid, 20 μM ATP and 10 μM H2DCFDA) was added, and the fluorescence intensity at 485 / 535 nm (excitation / emission) wavelength was detected after 30 minutes. The inhibitory activity of the compound on 5-lipoxygenase was calculated based on the fluorescence intensity of each group. The results are shown in Table 6. The inhibition rates of the above compounds on 5-lipoxygenase activity at a concentration of 2 μM were all >50%: Table 6 Inhibition rate of 5-lipoxygenase activity by sporechelin AE and sporechelin A1 in the cell-free system (%)

[0101] 6. In vitro anti-inflammatory activity evaluation test of spore sequestrant AE and spore sequestrant A1: This part uses bacterial lipopolysaccharide (LPS)-induced mouse peritoneal macrophage Raw264.7 inflammatory response model to evaluate the anti-inflammatory effect of the compounds. This model is a cell model widely used in various inflammatory injury diseases, and is also a commonly used model for anti-inflammatory drug screening and efficacy evaluation.

[0102] Cell culture and compound treatment: Raw264.7 cells were cultured at 3 × 10 cells / mL in DMEM medium (Gibco) containing 10% fetal bovine serum and 1% penicillin-streptomycin (Gibco). 4 / cm 2 The cells were plated in a 96-well plate at a density of 50 μL and cultured in a 37°C 5% CO2 cell culture incubator until 60-80% confluence was achieved. Then, 50 μL of 1 μg / mL LPS was added to make the final concentrations of 1 μM for spore chelator AE and spore chelator A1 and 5 μM for Dex. After 18 hours of induction, total RNA was extracted (the same method as above), and pro-inflammatory factors were detected by qRT-PCR. Tnfα and Cox2 The mRNA expression of genes was measured, and the cytotoxicity was evaluated by CCK-8 method under the same conditions. The primer sequences used are shown in Table 3. Compared with the model group, the inhibition rate of mRNA expression of inflammatory response marker genes by spore sequestrant AE and spore sequestrant A1 and the cytotoxicity results on Raw264.7 under this condition are shown in Table 7 and Fig.24As shown: Table 7 Inhibition rate of spore sequestrant AE and spore sequestrant A1 on mRNA expression of inflammatory response marker genes (%)

[0103] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A catechol compound, characterized in that: Has any of the following structural formulas: ; Wherein, R1 and R2 represent alkyl, phenyl or substituted phenyl.

2. The catechol compound according to claim 1, characterized in that R1 and R2 represent C1-C7 alkyl, phenyl or substituted phenyl; preferably, R1 and R2 represent C1-C3 alkyl, phenyl or substituted phenyl; more preferably, R1 represents methyl, ethyl, isopropyl, benzyl or p-hydroxybenzyl; R2 represents benzyl.

3. Use of the catechol compound according to claim 1 or 2 in the preparation of anti-fibrosis drugs.

4. Use of the catechol compound according to claim 1 or 2 in the preparation of anti-inflammatory drugs.

5. An anti-fibrosis drug, characterized in that: Containing the catechol compound or pharmaceutically acceptable salt thereof according to claim 1 or 2.

6. An anti-inflammatory drug, characterized in that: Containing the catechol compound or pharmaceutically acceptable salt thereof according to claim 1 or 2.

7. The method for preparing catechol compounds according to claim 1 or 2, characterized in that: The method comprises S1 and S2, wherein S1: fermenting and culturing Micromonospora to obtain a fermentation broth; S2: extracting and separating the catechol compound from the fermentation broth; preferably, the Micromonospora is Micromonospora sp. TMD166.

8. The method for preparing catechol compounds according to claim 7, characterized in that: The S2 includes S21~S22, S21: centrifuging the fermentation broth to obtain a supernatant and mycelium, taking the supernatant for extraction treatment to obtain a supernatant extract; S22: preliminarily separating the supernatant extract by gel column chromatography, then separating it by reverse phase silica gel column chromatography, gradient eluting with a solvent, and finally preparing and separating by HPLC to obtain catechol compounds.

9. The method for preparing catechol compounds according to claim 8, characterized in that: During the extraction treatment, the extraction solvent includes one or more of chloroform, dichloromethane, ethyl acetate and acetone.

10. The method for preparing catechol compounds according to claim 8, characterized in that: The medium used in the gel column chromatography separation includes Sephadex LH-20 or Tosoh Toyopearl HW-40; and / or, the medium used in the reverse phase silica gel column is C18 reverse phase silica gel; and / or, the chromatographic column used in the HPLC preparative separation includes C18 chromatographic column, C8 chromatographic column, C3 chromatographic column or phenyl bonded column; preferably, the mobile phase of the gel column chromatography includes one or more of chloroform, dichloromethane, ethyl acetate, methanol, ethanol and other alcohols with a carbon chain ≤4, acetone and butanone; or, a mixed solution of one or more of the above solvents and water; preferably, the solution used in the reverse phase silica gel column chromatography separation includes one or more of acetone aqueous solution, alcohol solution with a carbon chain ≤4, and acetonitrile aqueous solution; preferably, the mobile phase used in the HPLC preparative separation includes one or more of acetone aqueous solution, alcohol solution with a carbon chain ≤4, and acetonitrile aqueous solution.

Citation Information

Patent Citations

  • Fibrosis-suppressing agent

    JP1993271067A

Cited By

  • Bis (2, 3-dihydroxybenzamide) compound as well as preparation method and application thereof

    CN120829363A

  • A kind of double (2,3-dihydroxy benzamide) compound and its preparation method and application

    CN120829363B